HC Wainwright reaffirmed their buy rating on shares of TG Therapeutics (NASDAQ:TGTX) in a research note published on Tuesday morning, TipRanks reports. They currently have a $20.00 price objective on the biopharmaceutical company’s stock.
Several other research analysts also recently commented on the stock. BidaskClub raised shares of TG Therapeutics from a hold rating to a buy rating in a research note on Thursday, November 7th. ValuEngine downgraded shares of TG Therapeutics from a buy rating to a hold rating in a research note on Monday, October 21st. B. Riley began coverage on TG Therapeutics in a report on Wednesday, November 27th. They set a buy rating and a $12.00 price target on the stock. Finally, Zacks Investment Research cut shares of TG Therapeutics from a buy rating to a hold rating in a report on Friday, November 15th. Two research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company has a consensus rating of Buy and an average target price of $12.95.
Shares of TGTX opened at $9.42 on Tuesday. The company has a debt-to-equity ratio of 2.77, a current ratio of 1.00 and a quick ratio of 1.00. The business has a 50-day moving average of $7.44 and a 200 day moving average of $6.97. TG Therapeutics has a fifty-two week low of $3.32 and a fifty-two week high of $9.78.
TG Therapeutics (NASDAQ:TGTX) last posted its quarterly earnings data on Tuesday, November 12th. The biopharmaceutical company reported ($0.69) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.33). TG Therapeutics had a negative net margin of 123,130.93% and a negative return on equity of 2,411.79%. The business had revenue of $0.04 million for the quarter, compared to the consensus estimate of $0.04 million. On average, research analysts expect that TG Therapeutics will post -1.96 earnings per share for the current year.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Aperio Group LLC purchased a new stake in TG Therapeutics during the second quarter valued at $32,000. Bank of Montreal Can increased its position in TG Therapeutics by 1,119.0% in the second quarter. Bank of Montreal Can now owns 8,143 shares of the biopharmaceutical company’s stock worth $70,000 after buying an additional 7,475 shares in the last quarter. Centaurus Financial Inc. increased its position in TG Therapeutics by 12,400.0% in the second quarter. Centaurus Financial Inc. now owns 10,000 shares of the biopharmaceutical company’s stock worth $87,000 after buying an additional 9,920 shares in the last quarter. Tower Research Capital LLC TRC purchased a new stake in TG Therapeutics in the second quarter worth about $98,000. Finally, Virtu Financial LLC bought a new position in shares of TG Therapeutics in the third quarter worth about $69,000. 48.64% of the stock is currently owned by hedge funds and other institutional investors.
About TG Therapeutics
TG Therapeutics, Inc, a biopharmaceutical company, engages in developing and delivering medicines for patients with chronic lymphocytic leukemia (CLL), non-Hodgkin's Lymphoma (NHL), and Multiple Sclerosis (MS). It develops a robust B-cell directed research and development platform for identification of key B-cell pathways of interest and rapid clinical testing.
Featured Story: Dogs of the Dow
Receive News & Ratings for TG Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for TG Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.